TISIDB

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Single-pass type I membrane protein.
Domain	PF13895 Immunoglobulin domain PF07686 Immunoglobulin V-set domain
Function	Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Isoform 2 interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation.; FUNCTION: (Microbial infection) Acts as a receptor for adenovirus subgroup B.

> Gene Ontology [ TOP ]
Biological Process	GO:0001773 myeloid dendritic cell activation GO:0001819 positive regulation of cytokine production GO:0001878 response to yeast GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002224 toll-like receptor signaling pathway GO:0002237 response to molecule of bacterial origin GO:0002249 lymphocyte anergy GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002274 myeloid leukocyte activation GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002287 alpha-beta T cell activation involved in immune response GO:0002292 T cell differentiation involved in immune response GO:0002293 alpha-beta T cell differentiation involved in immune response GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response GO:0002309 T cell proliferation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002507 tolerance induction GO:0002517 T cell tolerance induction GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0002643 regulation of tolerance induction GO:0002644 negative regulation of tolerance induction GO:0002664 regulation of T cell tolerance induction GO:0002665 negative regulation of T cell tolerance induction GO:0002667 regulation of T cell anergy GO:0002668 negative regulation of T cell anergy GO:0002683 negative regulation of immune system process GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002828 regulation of type 2 immune response GO:0002830 positive regulation of type 2 immune response GO:0002870 T cell anergy GO:0002911 regulation of lymphocyte anergy GO:0002912 negative regulation of lymphocyte anergy GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0007159 leukocyte cell-cell adhesion GO:0007568 aging GO:0009615 response to virus GO:0009620 response to fungus GO:0010035 response to inorganic substance GO:0010038 response to metal ion GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0019058 viral life cycle GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030099 myeloid cell differentiation GO:0030217 T cell differentiation GO:0030258 lipid modification GO:0030260 entry into host cell GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0031349 positive regulation of defense response GO:0032496 response to lipopolysaccharide GO:0032623 interleukin-2 production GO:0032633 interleukin-4 production GO:0032641 lymphotoxin A production GO:0032663 regulation of interleukin-2 production GO:0032673 regulation of interleukin-4 production GO:0032681 regulation of lymphotoxin A production GO:0032743 positive regulation of interleukin-2 production GO:0032753 positive regulation of interleukin-4 production GO:0032761 positive regulation of lymphotoxin A production GO:0032943 mononuclear cell proliferation GO:0032944 regulation of mononuclear cell proliferation GO:0032946 positive regulation of mononuclear cell proliferation GO:0034138 toll-like receptor 3 signaling pathway GO:0034341 response to interferon-gamma GO:0035710 CD4-positive, alpha-beta T cell activation GO:0042035 regulation of cytokine biosynthetic process GO:0042089 cytokine biosynthetic process GO:0042092 type 2 immune response GO:0042093 T-helper cell differentiation GO:0042094 interleukin-2 biosynthetic process GO:0042097 interleukin-4 biosynthetic process GO:0042098 T cell proliferation GO:0042102 positive regulation of T cell proliferation GO:0042104 positive regulation of activated T cell proliferation GO:0042107 cytokine metabolic process GO:0042108 positive regulation of cytokine biosynthetic process GO:0042109 lymphotoxin A biosynthetic process GO:0042110 T cell activation GO:0042113 B cell activation GO:0042129 regulation of T cell proliferation GO:0042493 response to drug GO:0043011 myeloid dendritic cell differentiation GO:0043016 regulation of lymphotoxin A biosynthetic process GO:0043017 positive regulation of lymphotoxin A biosynthetic process GO:0043367 CD4-positive, alpha-beta T cell differentiation GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation GO:0044409 entry into host GO:0045064 T-helper 2 cell differentiation GO:0045076 regulation of interleukin-2 biosynthetic process GO:0045086 positive regulation of interleukin-2 biosynthetic process GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045402 regulation of interleukin-4 biosynthetic process GO:0045404 positive regulation of interleukin-4 biosynthetic process GO:0045580 regulation of T cell differentiation GO:0045582 positive regulation of T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045621 positive regulation of lymphocyte differentiation GO:0045622 regulation of T-helper cell differentiation GO:0045624 positive regulation of T-helper cell differentiation GO:0045628 regulation of T-helper 2 cell differentiation GO:0045630 positive regulation of T-helper 2 cell differentiation GO:0045785 positive regulation of cell adhesion GO:0046006 regulation of activated T cell proliferation GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046631 alpha-beta T cell activation GO:0046632 alpha-beta T cell differentiation GO:0046634 regulation of alpha-beta T cell activation GO:0046635 positive regulation of alpha-beta T cell activation GO:0046637 regulation of alpha-beta T cell differentiation GO:0046638 positive regulation of alpha-beta T cell differentiation GO:0046651 lymphocyte proliferation GO:0046718 viral entry into host cell GO:0046834 lipid phosphorylation GO:0046854 phosphatidylinositol phosphorylation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0050670 regulation of lymphocyte proliferation GO:0050671 positive regulation of lymphocyte proliferation GO:0050798 activated T cell proliferation GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051607 defense response to virus GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071241 cellular response to inorganic substance GO:0071248 cellular response to metal ion GO:0071396 cellular response to lipid GO:0071593 lymphocyte aggregation GO:0071706 tumor necrosis factor superfamily cytokine production GO:0097028 dendritic cell differentiation GO:0098542 defense response to other organism GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903555 regulation of tumor necrosis factor superfamily cytokine production GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:2000514 regulation of CD4-positive, alpha-beta T cell activation GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
Molecular Function	GO:0001618 virus receptor activity GO:0015026 coreceptor activity GO:0035004 phosphatidylinositol 3-kinase activity GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component	GO:0009897 external side of plasma membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs) hsa04620 Toll-like receptor signaling pathway hsa04672 Intestinal immune network for IgA production
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-389356: CD28 co-stimulation R-HSA-389357: CD28 dependent PI3K/Akt signaling R-HSA-389359: CD28 dependent Vav1 pathway R-HSA-389513: CTLA4 inhibitory signaling R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-388841: Costimulation by the CD28 family R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-180292: GAB1 signalosome R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-6783783: Interleukin-10 signaling R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-199418: Negative regulation of the PI3K/AKT network R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1257604: PIP3 activates AKT signaling R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-449147: Signaling by Interleukins R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04514 Cell adhesion molecules (CAMs)
hsa04620 Toll-like receptor signaling pathway
hsa04672 Intestinal immune network for IgA production

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-389356: CD28 co-stimulation
R-HSA-389357: CD28 dependent PI3K/Akt signaling
R-HSA-389359: CD28 dependent Vav1 pathway
R-HSA-389513: CTLA4 inhibitory signaling
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-180292: GAB1 signalosome
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CD86 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CD86 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23175469	Acute Myeloid Leukemia	Inhibit immunity	B7-2(+) AML cells significantly contributed to T-cell responses. In conclusion, Th-cell responses can be directly supported by B7-2(+) leukemia subpopulations. However, this interaction can facilitate the acquisition of a suppressive character that may contribute to immune evasion in myeloid leukemia.
19378341	Ovarian carcinoma	Promote immunity (T cell function)	Upon IFNgamma exposure, TAM purified from ovarian cancer ascites recover a M1 phenotype (IL-10(low), IL-12(high)), express high levels of CD86 and low levels of ILT3, enhance the proliferation of CD4(+) T lymphocytes and potentiate the cytotoxic properties of a MelanA-specific CD8(+) T cell clone.
27496866	Head and Neck Carcinoma	Promote immunity (T cell function); essential for immunotherapy	CD137 agonist mAb urelumab enhanced cetuximab-activated NK-cell survival, DC maturation, and tumor antigen cross-presentation. Urelumab boosted DC maturation markers, CD86 and HLA DR, and antigen-processing machinery (APM) components TAP1/2, leading to increased tumor antigen cross-presentation. These results suggest a beneficial effect of combination immunotherapy using cetuximab and CD137 agonist in HNC.
19188167	Colon Adenocarcinoma	Inhibit immunity	Here, we showed that short-term administration of anti-B7-1/B7-2 monoclonal antibodies in TRAMP mice leads to significant inhibited primary tumor growth and the size of metastatic lesions. The treatment is effective to inhibit MC38 colon cancer growth. Correspondingly, this treatment results in a transient reduction of Treg in both thymus and the periphery. In vivo cytotoxicity assay revealed T antigen-specific CTL effectors in anti-B7-treated but not control IgG-treated TRAMP mice.
18537185	Hepatocellular Carcinoma	Promote immunity	Ad-CD40L transduction exerted CD40/CD40L interactions between DCs, increasing DC immunostimulation with up-regulation of CD80/CD86- and interleukin-12 (IL-12) expression.
15981208	Renal Cell Carcinoma	Promote immunity	In contrast, in a HLA Class I-matched situation, B7-2 is more effective in the induction of IFN-gamma and GM-CSF secretion than B7-1, but both B7 molecules induce T cell proliferation equally efficient.

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CD86 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CD86 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.289	0.464
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.289	0.821
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.293	0.773
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.245	0.0249
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-2.086	0.0791
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.183	0.9
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.123	0.791
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.302	0.822
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.104	0.945
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.547	0.256
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.489	0.502
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.117	0.483

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CD86 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	8.2	-8.2	0.187
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	8.5	-8.5	0.32
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD86. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD86. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD86. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD86. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CD86 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CD86 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CD86
Name	CD86 molecule
Aliases	B7.2; B7-2; B-lymphocyte antigen B7-2; CD28LG2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; LAB ......
Chromosomal Location	3q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CD86 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CD86.

ID	Name	Drug Type	Targets	#Targets
DB00098	Antithymocyte immunoglobulin (rabbit)	Biotech	CD1A, CD4, CD86, FCGR2B, ITGAL, ITGAV, ITGB1, ITGB3, MR1	9
DB01281	Abatacept	Biotech	CD80, CD86	2
DB06681	Belatacept	Biotech	CD80, CD86	2

Browse CD86